Previous Close | 2.0400 |
Open | 2.1000 |
Bid | 2.0700 x 900 |
Ask | 2.2600 x 1400 |
Day's Range | 2.0600 - 2.1000 |
52 Week Range | 1.8500 - 5.0000 |
Volume | |
Avg. Volume | 104,429 |
Market Cap | 189.196M |
Beta (5Y Monthly) | 1.90 |
PE Ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
Subscribe to Yahoo Finance Plus to view Fair Value for IMMP
Encouraging efficacy results continue for patients with 2nd line PD-X refractory non-small cell lung cancer (NSCLC)Patients in this 2nd line setting had confirmed disease progression on anti-PD-1 / anti-PD-L1 (“PD-X”) based 1st line therapy1Key facts reported: Median Overall Survival (OS) from therapy with efti in combination with pembrolizumab is 9.7 months25% were progression free at 6 months and 36.5% were alive at 18 months2 Chemo-free therapy of efti in combination with pembrolizumab contin
Phase II TACTI-002 trial met its primary objective in 1st line non-small cell lung cancer (NSCLC) patients, with 38.6% Overall Response Rate and favourable anti-tumour activityBiomarker and multivariate analysis data from the completed Phase IIb AIPAC trial reported, confirming efti is activating the immune system and helping patients live longerFour world leading oncologists join the Clinical Advisory BoardWell-funded with ~$80 million in cash, giving Immutep an expected cash runway into early
SYDNEY, AUSTRALIA, July 06, 2022 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune diseases, is pleased to announce the grant of a new patent (number 7074341) entitled “Anti-LAG-3 Antibodies” by the Japanese Patent Office. This new Japanese patent follows the grant of the equivalent European patent announced in October 2020. The claims of the patent are directed to